Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/− murine hearts modelling the Brugada syndrome
Open Access
- 4 May 2007
- journal article
- Published by Wiley in The Journal of Physiology
- Vol. 581 (1), 255-275
- https://doi.org/10.1113/jphysiol.2007.128785
Abstract
Brugada syndrome (BrS) is associated with a loss of Na+ channel function and an increased incidence of rapid polymorphic ventricular tachycardia (VT) and sudden cardiac death. A programmed electrical stimulation (PES) technique assessed arrhythmic tendency in Langendorff‐perfused wild‐type (WT) and genetically modified (Scn5a+/−) ‘loss‐of‐function’ murine hearts in the presence and absence of flecainide and quinidine, and the extent to which Scn5a+/− hearts model the human BrS. Extra‐stimuli (S2), applied to the right ventricular epicardium, followed trains of pacing stimuli (S1) at progressively reduced S1–S2 intervals. These triggered VT in 16 out of 29 untreated Scn5a+/− and zero out of 31 WT hearts. VT occurred in 11 out of 16 (10 μm) flecainide‐treated WT and nine out of the 13 initially non‐arrhythmogenic Scn5a+/− hearts treated with (1.0 μm) flecainide. Quinidine (10 μm) prevented VT in six out of six flecainide‐treated WT and 13 out of the 16 arrhythmogenic Scn5a+/− hearts in parallel with its clinical effects. Paced electrogram fractionation analysis demonstrated increased electrogram durations, expressed as electrogram duration (EGD) ratios, with shortening S1–S2 intervals in arrhythmogenic Scn5a+/− hearts, and prolonged ventricular effective refractory periods (VERPs) in non‐arrhythmogenic Scn5a+/− hearts. Flecainide increased EGD ratios in WT (at 10 μm) and non‐arrhythmogenic Scn5a+/− hearts (at 1.0 μm), whereas quinidine (10 μm) reduced EGD ratios and prolonged VERPs in WT and arrhythmogenic Scn5a+/− hearts. However, epicardial and endocardial monophasic action potential recordings consistently demonstrated positive gradients of repolarization in WT, arrhythmogenic and non‐arrhythmogenic Scn5a+/− hearts under all pharmacological conditions. Together, these findings demonstrate proarrhythmic effects of flecainide in WT and Scn5a+/− murine hearts that recapitulate its clinical effects. They further attribute the arrhythmogenic phenomena observed here to re‐entrant substrates resulting from delayed epicardial activation despite an absence of transmural heterogeneities of repolarization, in sharp contrast to recent characterizations in ‘gain‐of‐function’Scn5a+/Δ murine hearts modelling the long‐QT(3) syndrome.Keywords
This publication has 88 references indexed in Scilit:
- Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Δ murine hearts modelling long QT syndrome 3The Journal of Physiology, 2006
- Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1The Journal of Physiology, 2003
- K+ Channel Structure-Activity Relationships and Mechanisms of Drug-Induced QT ProlongationAnnual Review of Pharmacology and Toxicology, 2003
- ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugsHeart, 2001
- Bipolar Leads for Use With Permanently Implantable Cardiac Pacing Systems: A Review of Limitations of Traditional and Coaxial Configurations and the Development and Testing of New Conductor, Insulation, and Electrode DesignsJournal of Investigative Surgery, 1997
- Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a mmulticenter trialThe American Journal of Cardiology, 1996
- Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndromeJournal of the American College of Cardiology, 1992
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient careAmerican Heart Journal, 1986
- Torsade de pointes due to quinidine: Observations in 31 patientsAmerican Heart Journal, 1984